Youth and cannabis: What’s the risk? – The Lewiston Tribune

🧠 The absence of systematic surveillance for cannabis use patterns and outcomes in youth populations represents a significant gap in our clinical understanding of this growing public health concern. While evidence suggests potential neurodevelopmental risks associated with adolescent cannabis exposure, the heterogeneity of products, potency levels, routes of administration, and individual vulnerability factors makes it difficult to quantify risk in clinical settings. Healthcare providers should be aware that coordinated monitoring systems remain fragmented across jurisdictions, limiting our ability to track population-level trends and identify emerging harms in real time. In clinical practice, this uncertainty argues for heightened vigilance during adolescent health visits: direct inquiry about cannabis use, counseling on potential developmental risks during critical brain maturation periods, and referral to addiction specialists when problematic use is identified. Until more robust epidemiologic data emerges, a precautionary approach informed by the neurobiological plausibility of harm remains prudent when advising young patients